A r t i c l e s We show that CASP1 and NLRP3 overexpression induces glucocorticoid resistance via CASP1 cleavage of the glucocorticoid receptor in its transactivation domain, reducing cellular levels of functional glucocorticoid receptor and diminishing glucocorticoid transcriptional effects. We further show that enforced expression of a glucocorticoid receptor that has been mutated to eliminate CASP1 cleavage sites mitigates glucocorticoid resistance due to CASP1 overexpression. Finally, we show that stably knocking down CASP1 expression with short hairpin RNA (shRNA) or reducing CASP1 activity with an inhibitory protein (CrmA) in CASP1-overexpressing leukemia cells increases cellular glucocorticoid receptor levels and markedly increases sensitivity to glucocorticoids.
RESULTS

Higher CASP1 and NLRP3 levels in glucocorticoid-resistant leukemia
The de novo sensitivity of primary leukemia cells to prednisolone differed widely (by >1,000-fold) among patients in three independent cohorts of children newly diagnosed with ALL ( Fig. 1a-c) . We found that CASP1 and NLRP3, both members of the NALP3 inflammasome, were the two most highly overexpressed genes sharing a common pathway in steroid-resistant ALL cells (Fig. 1d,e and Supplementary  Fig. 1) . The mean expression of CASP1 in steroid-resistant leukemia was 1.6-fold higher than in steroid-sensitive leukemia cells (P = 3.2 × 10 −7 ; Fig. 1d ), whereas the mean expression of NLRP3 was 2.4-fold higher in prednisolone-resistant leukemia cells across all three cohorts of patients (P = 3.5 × 10 −7 ; Fig. 1e ).
Methylation of CASP1 and NLRP3 regulates their expression
To understand the basis for the higher CASP1 and NLRP3 expression in glucocorticoid-resistant leukemia cells, we assessed the relationship between CASP1 and NLRP3 mRNA expression and methylation of the promoter regions of these genes in leukemia cells (Supplementary Fig. 2) . This analysis identified a highly significant relationship between the level of methylation of the CASP1 promoter and CASP1 mRNA expression in ALL cells (P = 1.4 × 10 −22 ; Fig. 1f and Supplementary Fig. 3a-c) . In a subset of patients enrolled on St. Jude Protocol XVI where matching germline DNA from normal lymphocytes was available for methylation analysis (n = 55), CASP1 promoter methylation did not differ significantly (paired t test, P = 0.495; Supplementary  Fig. 4 ) in lymphocyte germline DNA and leukemia cell DNA across the entire population. In contrast, of ten patients with significantly lower CASP1 promoter methylation in their ALL cells in comparison to their normal leukocytes, 70% were glucocorticoid resistant (n = 7), consistent with somatic CASP1 demethylation in glucocorticoid-resistant ALL cells. Methylation levels in the promoter region of NLRP3 were significantly higher in leukemia cell DNA than in germline leukocyte DNA (paired t test, P = 8.8 × 10 −11 ; Supplementary Fig. 4) , and the levels of NLRP3 promoter methylation in leukemia cells correlated significantly with NLRP3 expression in leukemia cells (P = 6.7 × 10 −4 ; Fig. 1g and Supplementary Fig. 3d-f ). Categorization of patients using k-means clustering of NLRP3 and CASP1 methylation levels significantly distinguished prednisolone-sensitive (blue symbols) from prednisolone-resistant (orange symbols) leukemia cells (Fisher's exact test for count data, P = 4.7 × 10 −7 ; Fig. 1h ).
CASP1 cleaves the glucocorticoid receptor
On the basis of a previous report of CASP1 cleavage of the androgen receptor 7 , we identified a putative CASP1 cleavage site (LLID) in the transactivation domain of the glucocorticoid receptor ( Fig. 2a,  top) , and we performed enzymatic assays that confirmed glucocorticoid receptor cleavage by recombinant CASP1 (Fig. 2a, bottom) . DCOG/COALL Protocols (n = 173) 35 30 25 20 Percentage of patients 15 10 5 Prednisolone LC 50 
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Site-directed mutagenesis of the sequence encoding the LLID motif ablated cleavage of the glucocorticoid receptor at this location ( Fig. 2b) and led to the identification of a secondary CASP1 cleavage site (IKQE) ( Fig. 2a, top) . CASP1-induced cleavage of the glucocorticoid receptor was inhibited by both tetrapeptide (Fig. 2a , bottom) and small molecule inhibitors (VX765 and VRT043198) of CASP1 (ref. 8; Fig. 2c ).
CASP1 overexpression increases glucocorticoid resistance
We hypothesized that CASP1 overexpression would increase resistance to glucocorticoids ( Fig. 2d) . We expressed full-length CASP1 in a human leukemia cell line (NALM-6) to test this hypothesis. Under standard conditions for activation of the NALP3 inflammasome and CASP1 (refs. 9-13), cells transduced with empty vector control virus did not show differences in their sensitivity to prednisolone or dexamethasone, whereas cells transduced with CASP1expressing virus had markedly higher LC 50 (drug concentration lethal to 50% of cells) values for prednisolone and dexamethasone ( Fig. 2e) . On average, CASP1 overexpression increased resistance to prednisolone by 16.9-fold (Student's t test, P = 5.7 × 10 −6 ) and resistance to dexamethasone by 5.3-fold (Student's t test, P = 1.2 × 10 −9 ), with a 35% reduction in glucocorticoid receptor levels by 24 h after inflammasome activation ( Fig. 2e) . This result was validated in a different human ALL cell line (697), where there was a similar increase in resistance to glucocorticoids ( Supplementary Fig. 5 ).
CASP1 blunts the transcriptional response to glucocorticoids
Because glucocorticoids regulate the expression of target genes by binding to the glucocorticoid receptor, triggering its translocation into the nucleus and association with a glucocorticoid response element (GRE) to increase or decrease gene transcription, we assessed the ability of glucocorticoids to influence global gene expression in the presence or absence of enforced expression of CASP1. We found markedly diminished glucocorticoid-induced changes in gene expression levels in cells with enforced expression of CASP1 in comparison to controls ( Fig. 3a,b) . Likewise, induction of Bim protein levels, encoded by BCL2L11, a known glucocorticoid response gene, was markedly 
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A r t i c l e s blunted in CASP1-overexpressing cells ( Fig. 3a , inset). BCL2L11 upregulation was also significantly blunted at the mRNA level in CASP1-overexpressing cells as compared to control cells (fold change = 1.39 ± 0.12 versus 1.78 ± 0.17; P = 0.024). Genome-wide assessment of changes in gene expression after glucocorticoid treatment (in 4 replicate experiments) identified 93 genes that were induced by at least 3-fold following glucocorticoid treatment of control cells, 64 (68%) of which had lower (by at least 25%) induction in CASP1-overexpressing cells. Among these genes, the mean induction in control cells was 8.4-fold, as compared to only 4.4-fold in CASP1-overexpressing cells (paired t test, P = 0.01). Analysis of the sequences of these genes (including 5 kb up-and downstream of each) showed a significant enrichment (46/93; 49%) of either known GREs (glucocorticoid receptor-binding motif; Supplementary  Table 1 , motifs 1-9; refs. [14] [15] [16] or a genomic region shown by chromatin immunoprecipitation and sequencing (ChIP-seq) experiments to bind the glucocorticoid receptor 14 , as compared to only 28% (1,409/5,000) of randomly selected, unchanged genes (Fisher's exact test, P = 2.2 × 10 −5 ). Inclusion of an additional motif containing the top two most frequent bases at each position of a previously reported motif 16 ( Supplementary Table 1 , motif 10) increased the percentage of upregulated genes with a GRE to 62% (58/93) of the transactivated genes. Of the 119 genes whose expression was downregulated by at least 50% following glucocorticoid treatment of control cells, 98 (82%) were downregulated to a lesser extent (by at least 25%) in CASP1-overexpressing cells. Among these genes, the mean reduction in control cells was 58%, as compared to only 33% in CASP1overexpressing cells (paired t test, P < 2.2 × 10 −16 ). Analysis of the sequences of these genes, including 5 kb up-and downstream, showed a significant enrichment (29/119; 24%) of binding motifs for nuclear factor (NF)-κB (a transcription factor known to interact with activated glucocorticoid receptor; Supplementary Table 1, motif 11) or a genomic region shown by ChIP-seq to bind to the glucocorticoid receptor 14 , as compared to randomly selected, unchanged genes (849/5,000; 17%; Fisher's exact test, P = 0.048). The top 50 most upregulated and a b Downregulated genes npg downregulated genes in control cells and their changes in expression in cells with enforced expression of CASP1 are depicted in Figure 3 , with the complete gene lists provided in Supplementary Tables 2-4 .
Additionally, CASP1 overexpression blunted genome-wide glucocorticoid receptor binding to DNA in response to prednisolone, as evidenced by ChIP-seq. The distribution of normalized read count ratios at all reproducible glucocorticoid receptor-binding sites identified across control and CASP1-overexpressing cells showed a more than fourfold enrichment of reads in control cells as compared to those overexpressing CASP1, and 96% of all glucocorticoid receptor binding events displayed stronger read enrichments in control cells ( Fig. 3c) , in line with a lower level of functional glucocorticoid receptor as a result of CASP1 overexpression. In support of these analyses, an assessment of the identified binding sites found a marked overlap in glucocorticoid receptor binding events ( Fig. 3e ) for control and CASP1-overexpressing cells, and we observed a 2.9-fold enrichment in the total number of binding sites in control cells (10,024 sites in control cells versus 3,467 sites in CASP1overexpressing cells). Notably, the top DNA-binding motifs identified for control and CASP1-overexpressing cells ( Fig. 3d) are consistent with the canonical glucocorticoid receptor binding motif. The extent of ChIP enrichment in control cells as compared to CASP1overexpressing cells is exemplified by the four genes shown in Figure 3f . Glucocorticoid receptor binding in CASP1-overexpressing cells consistently resulted in less ChIP enrichment than glucocorticoid receptor binding in control cells. Collectively, these data document a lower level of genome-wide glucocorticoid receptor occupancy in CASP1-overexpressing cells.
CASP1 and NLRP3 expression is higher in relapsed leukemia
To determine whether CASP1 and NLRP3 expression differed in leukemia cells at the time of disease recurrence ( Fig. 4) , we examined the mRNA expression levels of these genes in paired ALL cells obtained at diagnosis and relapse from 49 patients 17 . This analysis showed significantly higher expression of both CASP1 and NLRP3 in ALL cells at the time of relapse when compared to the corresponding samples obtained from the same patients at diagnosis (paired t test, P = 3.2 × 10 −4 and 4.2 × 10 −3 , respectively). Likewise, in a separate cohort of patients, we found that ALL cells at the time of disease recurrence (relapse) were more resistant to glucocorticoids when compared to the sensitivity of corresponding cells at the time of initial diagnosis (P = 9.72 × 10 −7 ; Fig. 4c ). 
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CASP1 inhibition reverses glucocorticoid resistance
To determine whether inhibition of CASP1 could diminish CASP1induced glucocorticoid receptor cleavage and increase sensitivity to glucocorticoid treatment, we first used shRNA to knock down overexpressed CASP1. This experiment showed that knockdown of CASP1 expression by ~50% ( Fig. 5a, shCASP1 ) reduced CASP1-induced glucocorticoid receptor cleavage (Fig. 5a, shCASP1 ) and markedly enhanced glucocorticoid sensitivity (prednisolone LC 50 = 12.8 ± 4.7 µM versus 570 ± 423.2 µM (mean ± s.e.m.), 44-fold reduction; t test, P = 0.028) ( Fig. 5c, shCASP1 ) in CASP1-overexpressing ALL cells when compared to cells transduced with scrambled, non-targeting shRNA (Fig. 5c, shNT) . Likewise, when we transduced CASP1-overexpressing NALM-6 cells with the gene encoding CrmA (cytokine response modifier A), a known inhibitor of CASP1 catalytic activity [18] [19] [20] , this blocked CASP1-induced glucocorticoid receptor cleavage ( Fig. 5b) and markedly increased sensitivity to glucocorticoids (prednisolone LC 50 = 3.2 ± 0.2 µM versus 137.3 ± 24.3 µM (mean ± s.e.m.), 43-fold reduction; t test, P = 0.011; Fig. 5d ) when compared to control cells transduced to express GFP.
We also overexpressed CrmA together with RFP or RFP alone in glucocorticoid-resistant primary leukemia cells that had a high level of CASP1 expression in comparison to several other glucocorticoidsensitive primary leukemia xenografts (data not shown). Overexpression of CrmA led to a diminution of de novo glucocorticoid resistance (dexamethasone LC 50 = 0.14 µM (95% confidence interval = 0.1426 × 10 −2 to 0.2773 µM) versus >10 µM; P < 1 × 10 −14 ; Supplementary Fig. 6a ) and partial restoration of glucocorticoid receptor protein levels (Supplementary Fig. 6b ) in comparison to control cells expressing RFP alone. The levels of CASP1 expression in glucocorticoid-resistant primary ALL cells isolated from two patients (prednisolone LC 50 = 1,387 µM and 206.4 µM) were comparable to those in glucocorticoid-resistant NALM-6 ALL cells in which heterologous CASP1 was overexpressed to recapitulate this mechanism of glucocorticoid resistance (Supplementary Fig. 7) .
Removal of CASP1 cleavage sites mitigates resistance
We overexpressed full-length wild-type glucocorticoid receptor or a glucocorticoid receptor that had been mutated to eliminate the CASP1 cleavage sites (with alanine residues substituted for the LLID and IKQE motifs identified in in vitro enzymatic assays) in leukemia cells overexpressing CASP1 in combination with either shRNA-based knockdown of the overexpressed CASP1 or non-targeting shRNA control. Enforced expression of wild-type glucocorticoid receptor was unable to reverse CASP1-induced glucocorticoid resistance, whereas expression of a glucocorticoid receptor without the CASP1 cleavage sites markedly attenuated CASP1-induced glucocorticoid resistance (9.4-fold reduction in LC 50 ), restoring sensitivity to levels similar to those for cells with shRNA-based knockdown of the overexpressed CASP1 ( Fig. 6) .
DISCUSSION
The present study has identified a new mechanism by which CASP1 and its activator, NLRP3, modulate the biological and pharmacological effects of glucocorticoids via cleavage of the glucocorticoid receptor. Glucocorticoids mediate their effects by binding to the glucocorticoid receptor, causing it to translocate to the nucleus, where it modulates the expression of genes that contain a GRE. Previous work has shown that low cellular levels of functional glucocorticoid receptor, due either to small interfering RNA (siRNA)-mediated knockdown 14, 21 , rare mutations in the human NR3C1 gene encoding the glucocorticoid receptor 22 or heterogeneity in the cellular levels of glucocorticoid receptor in leukemia cells caused by undefined mechanisms 23 , decrease sensitivity to glucocorticoids. However, it was previously not known that CASP1 can cleave the glucocorticoid receptor and thereby reduce functional receptor levels and modulate cellular response to glucocorticoids.
We have demonstrated that recombinant CASP1 cleaves the glucocorticoid receptor in its transactivation domain and that forced overexpression of CASP1 coupled with its activation via the NLRP3 inflammasome causes human leukemia cells to become more resistant to glucocorticoids. Overexpression of CASP1 without its activation via the NLRP3 inflammasome did not alter the glucocorticoid sensitivity of leukemia cells, demonstrating that catalytically active CASP1 is required for loss of glucocorticoid sensitivity. Further, overexpression of a glucocorticoid receptor lacking CASP1 cleavage sites mitigated the effects of CASP1 overexpression on leukemia cell sensitivity to glucocorticoids. Activation of the NALP3 inflammasome in the absence of CASP1 overexpression had only a small effect on glucocorticoid resistance, possibly due to activation of endogenous CASP1. Furthermore, our finding of higher expression of CASP1 and NLRP3 in leukemia cells at the time of disease relapse provides a plausible mechanism for previous observations that leukemia cells at relapse are more resistant to prednisolone than leukemia cells at initial diagnosis 19 . In support of this hypothesis, we observed markedly greater resistance to dexamethasone in ALL cells obtained from patients at the time of relapse. Likewise, using publically available data, we found that many glucocorticoid-resistant ALL cell lines 24, 25 and primary ALL xenografts 26, 27 express relatively high levels of CASP1 (Supplementary Fig. 8) . Collectively, this evidence indicates Figure 6 Expression of glucocorticoid receptor with both CASP1 cleavage sites mutated to AAAA mitigates CASP1-induced prednisolone resistance. NALM-6 cells overexpressing CASP1 cotransfected with either shRNA targeting CASP1 (shCASP1) or non-targeting, scrambled hairpin (shNT) were stably transduced with lentiviral vectors containing a wild-type glucocorticoid receptor (WT GR) or a glucocorticoid receptor in which both CASP1 cleavage sites had been eliminated (double-mutagenized glucocorticoid receptor, DM GR). The sensitivity (LC 50 ) of these cells to prednisolone was determined by MTT assay. Cells overexpressing the glucocorticoid receptor without CASP1 cleavage sites remained sensitive to glucocorticoids when CASP1 was overexpressed. The inset is an immunoblot depicting recombinant glucocorticoid receptor protein levels in cells at the time of the MTT drug sensitivity assays. Data are representative of three independent experiments; error bars, s.d.
npg that, although there are multiple mechanisms by which ALL cells can become resistant to glucocorticoids [28] [29] [30] , CASP1 overexpression in glucocorticoid-resistant ALL is not uncommon. Notably, when we knocked down CASP1 expression in CASP1overexpressing cells, we were able to reverse CASP1-induced glucocorticoid receptor cleavage and markedly increase sensitivity to glucocorticoids, suggesting CASP1 inhibition as a potential new therapeutic strategy to mitigate glucocorticoid resistance. There have been small molecule CASP1 inhibitors in clinical development 31 , although phase 2 clinical trials of these inhibitors for epilepsy failed to show therapeutic benefit and were terminated 31 . The lack of clinical efficacy of this class of agents is consistent with their inability to reverse glucocorticoid resistance in our CASP1-overexpressing cells, which may result from their poor penetration into cells (data not shown). Our experiments showing that CrmA inhibition of CASP1 catalytic activity restores sensitivity to glucocorticoids in CASP1overexpressing leukemia cells provide a proof of principle for this strategy and a strong rationale for future studies to identify small molecule CASP1 inhibitors that can achieve sufficient cellular concentrations to reverse glucocorticoid resistance in leukemia cells with elevated expression of CASP1.
CASP1 belongs to a family of cysteine proteases that cleave proteins following an aspartic acid residue. Produced as a proenzyme, CASP1 requires removal of its caspase activation and recruitment domain (CARD) for it to become an active enzyme 32 . CARD cleavage is mediated by the formation of inflammasomes, of which the most extensively characterized is the NALP3 inflammasome. NALP3 (encoded by NLRP3) can be activated by exposure to pathogen-associated molecular pattern or damage-associated molecular pattern molecules or by whole pathogens or environmental irritants 32 . There is also emerging evidence that the NALP3 inflammasome can form in response to host-derived molecules, including extracellular ATP, glucose or monosodium urate crystals 10, [32] [33] [34] . In vivo induction of the NALP3 inflammasome typically results in self-oligomerization, recruitment of the ASC (PYCARD) adaptor protein, and clustering and autoactivation of CASP1. CASP1 is known to have proinflammatory effects, including the activation of inflammatory cytokines (for example, interleukin-1β and interleukin-18). Our findings raise the possibility that, during inflammatory processes, CASP1 negatively regulates anti-inflammatory glucocorticoid signaling to further amplify the proinflammatory effects of the NALP3 inflammasome.
The significant effects we observed on glucocorticoid sensitivity by partial reduction of cellular glucocorticoid receptor levels are consistent with previous studies showing that haploinsufficiency for the glucocorticoid receptor (NR3C1) produces a number of phenotypes, including familial glucocorticoid resistance 35 and adrenal hyperplasia 36 , alters blood pressure, glucose levels and lipid homeostasis in corresponding haploinsufficient mice 37 and causes glucocorticoid resistance in Jurkat leukemia cells 38 .
The fact that not all glucocorticoid-responsive genes were affected by CASP1 overexpression likely reflects differences among genes in their sensitivity to activated glucocorticoid receptor as a transcription factor. Whether glucocorticoids cause transactivation or transrepression of a given gene is determined in part by the presence or absence of either a positive GRE, leading to transactivation, or a negative GRE, leading to transrepression. Glucocorticoids may also repress gene expression via binding of the activated glucocorticoid receptor to transcription factors such as NF-κB and AP-1 (refs. 39,40) . Although we found a significant enrichment of positive GREs among transactivated genes and an enrichment of negative GREs among transrepressed genes, our inability to find GREs in all glucocorticoid-responsive genes likely reflects the currently incomplete definition for GREs. Our ChIP-seq experiments showed that DNA binding by the glucocorticoid receptor is markedly diminished in CASP1-overexpressing cells. The broad spectrum of genes affected in CASP1-overexpressing cells indicates that our findings likely have broader implications, beyond the modulation of the anti-leukemic effects of glucocorticoids.
Taken together, our findings demonstrate a new mechanism whereby leukemia cells develop resistance to glucocorticoids via somatic epigenetic changes that cause overexpression of CASP1 and NLRP3, leading to enhanced CASP1-mediated cleavage of the glucocorticoid receptor and diminished cellular response to glucocorticoids. These findings provide the foundation for future efforts to identify small molecule inhibitors of CASP1 that can reverse this mechanism of glucocorticoid resistance and thereby improve the treatment of ALL and potentially other illnesses for which glucocorticoids are used therapeutically. 
ONLINE METHODS
Patients.
A total of 444 children aged 18 years or younger with newly diagnosed ALL were included in this study. Of these, 271 were enrolled on the St. Jude Total Therapy XV or XVI protocol, and 173 were enrolled on the 9th ALL Dutch Childhood Oncology Group (DCOG) protocol at Erasmus Medical Center, Sophia Children's Hospital (Rotterdam, the Netherlands) or on treatment protocol 92 or 97 of the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL; Hamburg, Germany). Patients were enrolled in these studies if they had a diagnosis of ALL, were younger than 18 years of age and had not been previously treated for ALL. In an additional cohort of 49 pediatric patients with relapsed B-precursor ALL, cryopreserved bone marrow samples collected at diagnosis and relapse from the Children's Oncology Group (COG) were subjected to gene expression analysis as previously described 17 . All patients in the relapse cohort had a bone marrow or bone marrow and central nervous system combined relapse and had been initially treated on COG protocols for newly diagnosed ALL 17 . In a separate cohort of patients enrolled at St. Jude Children's Research Hospital, the LC 50 for dexamethasone was measured at the time of diagnosis and relapse. Written informed consent from all patients or their parents or guardians, and assent from the patients, were obtained, as appropriate. The research and use of these samples was approved by the institutional review board at the host institution where the samples were collected.
Gene expression analyses.
Total RNA was extracted with TriReagent (Molecular Research Center) from freshly isolated or cryopreserved mononuclear cell suspensions from patient bone marrow aspirates obtained at diagnosis. In the COG relapse cohort, RNA samples were extracted from leukemia cells derived from patient bone marrow aspirates obtained at the time of original diagnosis and again at the time of disease recurrence. All gene expression microarrays were performed by the St. Jude Children's Research Hospital Hartwell Center for Bioinformatics and Biotechnology. High-quality RNA was hybridized to the HG-U133A (GPL96) or HG-U133 Plus 2.0 (GPL570) oligonucleotide microarrays in accordance with the manufacturer's protocol (Affymetrix). These microarrays contain 22,283 and 54,675 gene probe sets, representing approximately 18,400 and 47,400 human transcripts, respectively. Gene expression data were processed with MAS5 (ref. 41) using the affy 42 Bioconductor 43 R project package or using Affymetrix Microarray Suite version 5.0 (refs. 44,45) as previously described 28 .
DNA methylation analyses. DNA was isolated at the time of diagnosis from leukemia cells obtained from patients via bone marrow aspirates. Genomewide DNA methylation status was determined using either an Infinium HumanMethylation27 BeadChip kit or an Infinium HumanMethylation450 BeadChip kit in accordance with the manufacturer's protocol (Illumina). HumanMethylation27 BeadChip experiments were performed at either the Emory Integrated Genomics Core (EIGC; Atlanta) or the Wellcome Trust Centre for Human Genetics Genomics Lab (Oxford). HumanMethylation450 BeadChip experiments were performed at the Heflin Center for Genomic Science at the University of Alabama at Birmingham (Birmingham, Alabama, USA). DNA methylation status was classified as low if the β value 46 was less than or equal to 0.25 and as high if the β value was greater than 0.25.
Statistical analyses.
Analyses were performed using R software unless otherwise specified. Exact Wilcoxon Mann-Whitney rank-sum tests were used for analyses of differential gene expression and differential DNA methylation, and Stouffer's z-score method was used for meta-analysis 47 . For box plots, the upper and lower values of each box depict the 75th and 25th percentiles, respectively, the solid line depicts the group median, and the top and bottom of each dashed vertical line depict the most extreme data points that were no more than 1.5 times the interquartile range (75th percentile-25th percentile) from the box. k-means clustering analysis with k = 2 was used for DNA methylation data and either untransformed or log-transformed gene expression data, with Fisher's exact test applied to determine the significance of clustering. Fisher's exact test was used to assess the significance of the enrichment of known GREs. for drug discovery (Enzo Life Sciences, BML-AK701-0001) was incubated at 30 °C with wild-type or mutant glucocorticoid receptor in the presence (10 µM, unless otherwise indicated) or absence of inhibitors, (Ac-YVAD-CHO, Enzo Life Sciences, BML-P403-9090), VX765 and VRT-043198. Whole-cell lysates for enzyme assays were prepared in CASP1 assay buffer (Enzo Life Sciences, KI-111) consisting of 50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 1 mM EDTA and 10% glycerol.
Site-directed mutagenesis. Site-directed mutagenesis was performed on the NR3C1 sequence using a QuikChange Site-Directed Mutagenesis kit (Stratagene). Mutagenesis of the sequence encoding the LLID motif was performed in four sequential mutagenesis reactions of the NR3C1 sequence encoding Myc-DDK-tagged protein (Origene, RC220189). The following mutagenesis primers were used: MutF1-4-NR3C1 and MutR1-4-NR3C1 (Supplementary Table 5 ). Mutagenesis of the sequence encoding the IKQE motif was performed in two sequential mutagenesis reactions of the sequence for LLID-mutated NR3C1. The following mutagenesis primers were used: MutF5-6-NR3C1 and MutR5-6-NR3C1 (Supplementary Table 5 ).
Successful mutagenesis was confirmed by Sanger sequencing.
Sensitivity of leukemia cells to glucocorticoids.
Leukemia cells were isolated at diagnosis from patient bone marrow aspirates. If the leukemia cell percentage from diagnostic bone marrow samples was less than 90%, magnetic activated cell sorting (Miltenyl Biotec) was performed to further enrich leukemia cells. If red blood cell contamination was greater than 30%, red blood cell lysis was performed. Cells were centrifuged at 300g for 5 min and resuspended in RPMI-1640 supplemented with 2 mM l-glutamine, 20% heat-inactivated FBS, 1× antibiotic-antimycotic solution (Life Technologies) and 1× ITS solution (Life Technologies) at a concentration of 2 million cells/ml. Then, 80 µl of this leukemia cell suspension was plated into each experimental well of roundbottom 96-well plates. We added 20 µl per well of decreasing concentrations of prednisolone, and plates were incubated for 96 h in a humidified incubator with 5% CO 2 at 37 °C. For the final 6 h, 10 µl of 5 mg/ml MTT (3-4,5-dimethylthiazol-2,5-diphenyl tetrazolium bromide) was added to each experimental well. Drug resistance assays in the NALM-6 and 697 cell lines (Leibniz Institut DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen)) were performed using between 0.25 and 2.5 million cells/ml. Assays were developed and performed as described for primary ALL cells. LC 50 values were determined for patients at diagnosis or relapse as previously described 28 ; consistent with previous analyses, glucocorticoid-resistant ALL was defined as having an LC 50 of 64 µM or greater, whereas glucocorticoid-sensitive ALL was defined as having an LC 50 of less than 0.1 µM. Among patients treated on the XV protocol (the only uniformly treated cohort with sufficient follow-up data to assess event-free survival), those whose samples were classified as sensitive to prednisolone (LC 50 < 0.1 µM) had a significantly better treatment outcome than the other patients (5-year event-free survival of 95.6% versus 82.7%; P = 0.01, log-rank test).
Enforced expression of CASP1. Full-length CASP1 cDNA (Origene, RC218364) was subcloned into a lentiviral backbone (System Biosciences, CD527A-1), in frame with a puromycin resistance gene encoding protein linked to T2A self-cleaving peptide. Lentivirus was produced in HEK293T cells (American Type Culture Collection), and the NALM-6 leukemia cell line was transduced. After 72 h, cells were selected with 2.5 µg/ml puromycin. Where indicated, cells were treated with 10 µg/ml LPS (Invivogen) followed 2 h later by 5 mM ATP (Roche). The HEK293T, NALM-6 and 697 cell lines were routinely authenticated and screened for mycoplasma.
Expression of mutant glucocorticoid receptor without CASP1 cleavage sites.
The sequence for doubly mutated NR3C1 (encoding mutated LLID and IKQE motifs) was subcloned into the pLX304 (ref. 48 ) lentiviral backbone (Addgene plasmid 25890). Lentivirus was produced in HEK293T cells, and NALM-6 leukemia cell lines with CASP1 overexpression and shRNA directed against CASP1 or a non-targeting shRNA were transduced. After 72 h, cells were selected with blasticidin.
Expression of GFP and CrmA. cDNA encoding GFP (Addgene plasmid 15301) 49 or CrmA (Addgene plasmid 11832) 50 was subcloned into the npg pLX304 (ref. 48 ) lentiviral backbone (Addgene plasmid 25890). Lentivirus was produced in HEK293T cells, and NALM-6 leukemia cell lines with CASP1 overexpression and shRNA directed toward CASP1 or a non-targeting shRNA were transduced. Seventy-two hours after transduction, cells were selected with blasticidin (15 µg/ml).
Immunoblotting. In brief, cells were pelleted by centrifugation, washed once with PBS and lysed with RIPA buffer or CASP1 assay buffer (Enzo Life Sciences, KI-111). Equal amounts of protein (1-20 µg) were separated on 4-12% Novex Bis-Tris gels (Life Technologies) and then transblotted to PVDF membranes (Life Technologies). Antibody to glucocorticoid receptor (1:1,000-1:10,000 dilution; BD, 611227), CASP1 p20 (1:1,000 dilution; Adipogen, AG-20B-0048), DDK tubulin (1:1,000 dilution; Origene, TA50011), Bim (1:1,000 dilution; Cell Signaling Technology, 2819), tubulin (1:1,000 dilution; Santa Cruz Biotechnology, sc-8035) or HSP90 (1:1,000 dilution; Cell Signaling Technology, 4874) was used as primary antibody followed by incubation with appropriate horseradish peroxidase (HRP)-conjugated secondary IgG (1:1,000 dilution; Dako). Immunocomplexes were visualized by chemiluminescence using a Chemidoc Imager (Bio-Rad). Signal intensities for CASP1 and glucocorticoid receptor were quantified using Quantity One software (Bio-Rad) and normalized for the signal intensity of the loading control in the same lane.
Glucocorticoid-induced changes in gene expression. NALM-6 cells transduced with either empty vector (control) or CASP1-containing lentiviral particles were treated with or without LPS and ATP, with or without 0.3 mM prednisolone, for 24 h. RNA was extracted and hybridized to Affymetrix PrimeView oligonucleotide microarrays, and data were processed with RMA. For a gene to be included among those that were transactivated by glucocorticoids, the median level of its mRNA expression from four replicate experiments had to increase in control cells by at least threefold. For a gene to be included among those that were transrepressed by glucocorticoids, the median level of its mRNA expression had to decrease by at least 50%.
Chromatin immunoprecipitation and sequencing. NALM-6 cells transduced with either empty vector (control) or CASP1-containing lentiviral particles were treated with or without LPS and ATP, with or without 0.3 mM prednisolone, for 24 h. ChIP-seq was performed with an antibody to the glucocorticoid receptor (Santa Cruz Biotechnology, sc-1003), as previously described 51 . Briefly, cross-linking was performed with formaldehyde (1% final concentration) for 10 min at room temperature, and cells were then incubated with glycine (0.125 M final concentration) for 5 min to stop the cross-linking reaction. Cells were pelleted, washed with 1× PBS containing protease inhibitors (Roche Protease Inhibitor Cocktail Tablets, 11836153001) and stored at −80 °C before further experimentation. Cross-linked cell pellets were resuspended in cold lysis buffer (5 mM PIPES, pH 8.0, 85 mM KCl and 0.5% NP-40) containing protease inhibitors (Roche Protease Inhibitor Cocktail Tablets), and lysates were centrifuged to isolate nuclei. Each pellet was resuspended in cold RIPA lysis buffer (1× PBS, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS). Sonication was performed using a Bioruptor sonication system (Diagenode). Sonicated chromatin was added to DynaBeads (Invitrogen) coated with antibody to glucocorticoid receptor (Santa Cruz Biotechnology, sc-1003) and incubated overnight at 4 °C. The solution was washed with a lithium chloride wash solution (100 mM Tris, pH 7.5, 500 mM lithium chloride, 1% NP-40 and 1% sodium deoxycholate) at 4 °C and with a final wash using 1× TE buffer. DynaBeads were resuspended in elution buffer (1% SDS and 0.1 M sodium bicarbonate) and placed at 65 °C to reverse cross-links. DNA was purified, and standard library preparation was performed before sequencing on an Illumina HiSeq 2000 sequencer. Glucocorticoid receptor-binding sites were identified using the MACS peak caller 52 .
ChIP-seq analyses. Reproducible glucocorticoid receptor ChIP-seq binding events were identified by a comparison of glucocorticoid receptor genome binding coordinates across replicate ChIP-seq experiments. Normalized read counts were assessed by compiling all reproducible binding events from control and CASP1-overexpressing cells (unique and common to both cell types) and determining the number of reads, normalized to the total number of aligned reads per ChIP experiment, mapping to the 100-bp fragment of DNA centered on each ChIP-seq binding site summit for all ChIP-seq replicate experiments. The average normalized read counts for each condition were determined and used to determine the ratio of read counts between control and CASP1overexpressing cells. The MEME program was used to identify enriched motifs at glucocorticoid receptor-binding sites 53 . Normalized read count ratios are defined as next-generation sequencing reads for control cells divided by those for CASP1-overexpressing cells, and a reproducible peak was defined as being identified by both replicate ChIP-seq experiments in each cell type.
Expression of CASP1 and NLRP3 in leukemia cells at the time of disease relapse versus at diagnosis. Gene expression was assessed at diagnosis and relapse as previously described 17 . This data set was processed with MAS5 (ref. 41) using the affy 42 Bioconductor 43 R project package and then quantile normalized. A paired t test was used for comparison of the matching diagnosis and relapse data. In a separate cohort of patients enrolled at St. Jude Children's Research Hospital, LC 50 for dexamethasone was measured at the time of diagnosis or relapse.
Expression analysis of glucocorticoid-sensitive and -resistant xenograft ALLs.
Affymetrix U133 Plus 2 expression data for primary ALL cells expanded as xenografts in mice were downloaded from the Pediatric Preclinical Testing Program and were processed with MAS5 using the affy 42 Bioconductor 43 R project package. Expression data were log 2 transformed, and the ALL xenografts were categorized as either sensitive or resistant to dexamethasone on the basis of their in vivo response to glucocorticoids 26, 27 . Xenografts determined to exhibit partial (intermediate) or complete resistance in vivo were categorized as resistant, and those that were sensitive in vivo were categorized as sensitive 26, 27 .
Expression analysis of glucocorticoid-sensitive and -resistant NCI60 ALL cell lines. Expression data for NCI60 ALL cell lines (Chiron Pharmaceuticals) were constant translated (by adding 0.1 to each value) to eliminate zero values before log 2 transformation and were combined with the expression data for xenografts ( Supplementary Fig. 7 ) measured from RNA isolated at diagnosis. Additionally, expression data from NALM-6 cells were obtained and combined with this data set. Data were median centered and scaled by dividing by the intrasample standard deviation, followed by quantile normalization. NCI60 drug sensitivity measurements showed that all cell lines in the leukemia panel, except CCRF-CEM, were resistant to prednisolone (Developmental Therapeutics Program National Cancer Institute/US National Institutes of Health accession NSC 19987, September 2014 release).
